Given that a very high frequency (>93%) of KRAS mutations has been observed in pancreatic cancer patients15, elucidating interactions among GP2 variants, KRAS oncogenic mutations, and other potential effector genes would provide insights into pancreatic carcinogenesis. This evidence concerns the gene GP2 and familial pancreatic carcinoma.